NewEdge Advisors LLC Buys 231,715 Shares of Gilead Sciences, Inc. $GILD

NewEdge Advisors LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 144.2% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 392,435 shares of the biopharmaceutical company’s stock after purchasing an additional 231,715 shares during the period. NewEdge Advisors LLC’s holdings in Gilead Sciences were worth $54,694,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. First Nebraska Trust Co purchased a new stake in Gilead Sciences in the 1st quarter worth approximately $530,000. Avidity Partners Management LP purchased a new position in Gilead Sciences during the first quarter valued at approximately $2,787,000. Allen Capital Group LLC lifted its holdings in Gilead Sciences by 4.9% during the first quarter. Allen Capital Group LLC now owns 2,400 shares of the biopharmaceutical company’s stock valued at $334,000 after purchasing an additional 112 shares in the last quarter. Axiom Investment Management LLC bought a new position in shares of Gilead Sciences in the first quarter worth approximately $677,000. Finally, J. Derek Lewis & Associates Inc. boosted its position in shares of Gilead Sciences by 7.1% in the first quarter. J. Derek Lewis & Associates Inc. now owns 3,020 shares of the biopharmaceutical company’s stock worth $421,000 after purchasing an additional 200 shares during the period. Institutional investors own 83.67% of the company’s stock.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported second-quarter revenue of $7.8 billion, above the roughly $7.4 billion consensus estimate. Product sales excluding Veklury rose 10% year over year to $7.6 billion, led by HIV medicines and Trodelvy. GILD Q2 Earnings Beat
• Positive Sentiment: Management raised its HIV growth outlook to 9%–10% and highlighted rapid adoption of Yeztugo, its HIV prevention treatment. PrEP sales reportedly doubled to approximately $1 billion, supporting the view that HIV remains Gilead’s primary growth engine. Q2 Earnings Call Highlights
• Positive Sentiment: Several analysts remain constructive: Cantor Fitzgerald reiterated an Overweight rating with a $155 target, while Needham reaffirmed Buy with a $170 target. Gilead also declared its $0.82 quarterly dividend, providing continued income support.
• Neutral Sentiment: The quarter was described as operationally strong, but reported earnings guidance remains negative because of acquisition-related charges and elevated research spending. The company’s 2026 base-business sales outlook is approximately $29.8 billion–$30.1 billion.
• Negative Sentiment: Gilead posted a $6.75 per-share quarterly loss versus $2.01 of earnings a year earlier. The loss was driven largely by acquisition-related costs, increasing concern about near-term profitability despite the revenue beat. Strong Quarter Hidden Behind Ugly Earnings
• Negative Sentiment: MSD and Gilead discontinued a Phase III Trodelvy-Keytruda study after lacklustre interim data. The failure weakens expectations for expanding Trodelvy’s use in combination therapy and adds uncertainty to Gilead’s oncology growth strategy. Trodelvy-Keytruda Study Discontinued
• Negative Sentiment: Veklury sales continued to decline sharply, while AIDS Healthcare Foundation criticized Gilead’s HIV pricing and access policies. The controversy could create reputational or longer-term market-access risks. CEO Daniel O’Day’s planned sale of 15,000 shares was a minor additional negative signal.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $132.27, for a total value of $396,810.00. Following the sale, the chief financial officer directly owned 173,191 shares of the company’s stock, valued at approximately $22,907,973.57. The trade was a 1.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $130.31, for a total value of $1,954,650.00. Following the completion of the sale, the chief executive officer owned 592,133 shares in the company, valued at $77,160,851.23. This represents a 2.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 82,000 shares of company stock worth $10,641,790 over the last 90 days. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Trading Down 0.7%

Gilead Sciences stock opened at $130.86 on Friday. Gilead Sciences, Inc. has a 1 year low of $108.46 and a 1 year high of $157.29. The firm’s 50 day moving average price is $129.43 and its 200-day moving average price is $136.22. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.14 and a quick ratio of 1.77. The stock has a market cap of $162.47 billion, a P/E ratio of -49.01 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. The firm had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. Gilead Sciences’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.01 earnings per share. On average, equities analysts predict that Gilead Sciences, Inc. will post -0.65 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio is 44.69%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on GILD. Rothschild & Co Redburn decreased their price objective on shares of Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Leerink Partners downgraded shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $146.00 to $127.00 in a report on Tuesday, July 21st. Wall Street Zen lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. The Goldman Sachs Group raised their price target on Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a report on Friday, April 17th. Finally, Citigroup boosted their price objective on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Twenty-five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $158.04.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.